Skip to main content
Krishnansu Tewari, MD, Obstetrics & Gynecology, Orange, CA, Providence St. Joseph Hospital Orange

KrishnansuSujataTewariMD

Obstetrics & Gynecology Orange, CA

Gynecologic Oncology

Professor & Gynecologic Oncologist, Director of the Division of Gynecologic Oncology

Dr. Tewari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tewari's full profile

Already have an account?

  • Office

    The City Tower
    333 City Blvd, West - Suite 1400
    Orange, CA 92868
    Phone+1 714-456-8020
    Fax+1 714-456-6632
  • Is this information wrong?

Summary

  • Dr. Krishnansu Tewari is an obstetrician/gynecologist in Orange, CA and is affiliated with multiple hospitals in the area, including St. Joseph Hospital Orange, UCI Medical Center, Long Beach Medical Center, Los Alamitos Medical Center, Saddleback Medical Center, MemorialCare, Orange Coast Memorial Medical Center, and St. Jude Medical Center. He received his medical degree from University of California, Irvine, School of Medicine and has been in practice 27 years. He specializes in gynecologic oncology and is experienced in fallopian tube carcinoma, hysterectomy, gynecologic oncology, cytoreductive surgery for ovarian cancer and advanced surface peritoneal malignancies, and robotic surgery for endometrial cancer.

Education & Training

  • Harvard T. H. Chan School of Public Health
    Harvard T. H. Chan School of Public HealthCertificate of Participation, Leadership Course for Academic Physicians in New Director Roles, 2018 - 2018
  • University of California (Irvine)
    University of California (Irvine)Fellowship, Gynecologic Oncology, 1998 - 2002
  • University of California (Irvine)
    University of California (Irvine)Residency, Obstetrics and Gynecology, 1994 - 1998
  • University of California, Irvine, School of Medicine
    University of California, Irvine, School of MedicineClass of 1994
  • University of California, Berkeley
    University of California, BerkeleyB.S., Molecular Biology, 1983 - 1990
  • University of California, Berkeley
    University of California, BerkeleyB.S., Molecular Biology, 1983 - 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1996 - 2025
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • Top Doctors:LA Area Castle Connolly, 2013
  • Top Doctors:San Diego Area Castle Connolly, 2013
  • Presidential Award for Most Outstanding Abstract 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: A phase III NRG Oncology/Gynecologic Oncology Gro...  
    Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O�Malley DM, Robiso..., J Clin Oncol, 1/5/2018
  • Predictive modeling for determination of microscopic residual disease at primary cytoreduction: A NRG Oncology/Gynecologic Oncology Group 182 Study  
    Horowitz NS, Maxwell LG, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS,..., Gynecol Oncol, 1/1/2018
  • Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: A NRG Oncology/Gynecologic Oncology Group Study  
    Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casedei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J..., Clin Cancer Res, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Final protocol-specified overall survival and updated toxicity analysis in the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cer...
    Tewari KS, Sill MW, Long HJ III, Penson RT, Huang HQ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael H, Monk BJ, Annual Meeting of the European Society of Medical Oncology, Madrid, Spain, 1/26/2014
  • Impact of race, socioeconomic status, and the health system on the treatment of advanced-stage ovarian caner in California
    Long BJ, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE, 45th Annual Meeting on Women�s Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/22/2014
  • Use of a dedicated pulley system to reestablish continuity of the vagina with the uterus at the time of fertility-preserving robotic assisted laparoscopic radical trac...
    Brueseke TJ, Tewari KS, 45th Annual Meeting on Women�s Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/22/2014
  • Join now to see all

Lectures

  • GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in line recurr... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Landmark Careers and Landmark Clinical Trials: Defining the Message for the Next Generation of Gynecologic Oncologists 
    1/22/2014
  • Refining therapeutic strategies in advanced cervical cancer: Focus on angiogenesis 
    Manchester Grand Hyatt Hotel, San Diego, CA - 1/7/2014
  • Join now to see all

Other

  • Newly diagnosed with ovarian cancer? Start here. In: Special Report � Ovarian Cancer 
    Tewari KS, Women Magazine
    1/1/2014
  • The highlights: Advances in screening and management of ovarian cancer � news from Annual Meetings of the Society of Gynecologic Oncology and the American Society of C... 
    Tewari KS, Women Magazine
    1/1/2013
  • Supreme Court Ruling a Major Victory for Women�s Health 
    Tewari KS, The Female Patient
    1/1/2012
  • Join now to see all

Press Mentions

  • Nanodrug Treatment for Ovarian Cancer Leads to 80% Survival Rate in Animals
    Nanodrug Treatment for Ovarian Cancer Leads to 80% Survival Rate in AnimalsApril 27th, 2023
  • Two Promising Targets in Advanced Cervical Cancer
    Two Promising Targets in Advanced Cervical CancerApril 25th, 2023
  • Questions over Value of Bevacizumab in Many Cancers
    Questions over Value of Bevacizumab in Many CancersNovember 21st, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations